At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNXT RenovoRx Inc
Trading 03-20 10:07:49 EDT
0.9968
-0.0132
-1.31%
High1.03Low0.9909Vol49.36K
Open1.03D1 Closing1.01Amplitude3.87%
Mkt Cap36.53MTradable Cap30.00MTotal Shares36.65M
T/O49.94KT/O Rate0.16%Tradable Shares30.09M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

RenovoRx to host Q4 and full-year 2025 financial results conference call
Reuters  ·  20:33
RenovoRx to host Q4 and full-year 2025 financial results conference call
BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
Reuters  ·  03-19 01:49
BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
Reuters  ·  03-18 21:11
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
BUZZ-RenovoRx rises after $10 mln private stock sale to fund cancer trial, device rollout
Reuters  ·  03-18 20:54
BUZZ-RenovoRx rises after $10 mln private stock sale to fund cancer trial, device rollout
BRIEF-Renovorx Announces $10 Million At Market Private Placement
Reuters  ·  03-18 20:37
BRIEF-Renovorx Announces $10 Million At Market Private Placement
RenovoRx announces USD 10 million private placement of common stock and warrants
Reuters  ·  03-18 20:35
RenovoRx announces USD 10 million private placement of common stock and warrants
RenovoRx Inc - to Issue 10.6 Mln Shares at $0.938 per Share With 50% Warrant Coverage
THOMSON REUTERS  ·  03-18 20:35
RenovoRx Inc - to Issue 10.6 Mln Shares at $0.938 per Share With 50% Warrant Coverage
RenovoRx Names Ramtin Agah Executive Chairman
Reuters  ·  02-27
RenovoRx Names Ramtin Agah Executive Chairman
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
GlobeNewswire  ·  02-27
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
RenovoRx to Present TAMP Therapy Platform Pancreatic Cancer PET/CT Findings at 2026 Society of Interventional Radiology Annual Scientific Meeting
Reuters  ·  02-26
RenovoRx to Present TAMP Therapy Platform Pancreatic Cancer PET/CT Findings at 2026 Society of Interventional Radiology Annual Scientific Meeting
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and RenovoRx (RNXT)
TIPRANKS  ·  02-18
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and RenovoRx (RNXT)
RenovoRx Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  02-17
RenovoRx Is Maintained at Buy by Ascendiant Capital
BRIEF-Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives
Reuters  ·  02-10
BRIEF-Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives
RenovoRx - Formation of Renovocath Medical Advisory Board to Support Clinical and Strategic Initiatives
THOMSON REUTERS  ·  02-10
RenovoRx - Formation of Renovocath Medical Advisory Board to Support Clinical and Strategic Initiatives
Press Release: RenovoRx Establishes RenovoCath(R) Medical Advisory Board
Dow Jones  ·  02-10
Press Release: RenovoRx Establishes RenovoCath(R) Medical Advisory Board
RenovoRx appoints Voll as Chief Financial Officer
TIPRANKS  ·  02-05
RenovoRx appoints Voll as Chief Financial Officer
RenovoRx Names Mark Voll Chief Financial Officer
Reuters  ·  02-05
RenovoRx Names Mark Voll Chief Financial Officer
Press Release: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Dow Jones  ·  02-05
Press Release: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
RenovoRx Unveils Clinical Data Supporting TAMP Therapy Platform at SIO 2026 Meeting
Reuters  ·  02-04
RenovoRx Unveils Clinical Data Supporting TAMP Therapy Platform at SIO 2026 Meeting
RenovoRx Announces Clinical Data Supporting the Tamp™ Therapy Platform Will Be Presented at the Sio 2026 Annual Scientific Meeting
THOMSON REUTERS  ·  02-04
RenovoRx Announces Clinical Data Supporting the Tamp™ Therapy Platform Will Be Presented at the Sio 2026 Annual Scientific Meeting

Introduction

Company Name.
RenovoRx Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Issue price:
--